Want to see AU:MAP full AI Analyst Report?
MAP Stock Chart & Stats
AU$0.08
>-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.11
Previous CloseN/A
Volume476.46K
Average Volume (3M)469.77K
Market Cap
AU$28.01M
Enterprise ValueAU$12.08M
Total Cash (Recent Filing)AU$11.27M
Total Debt (Recent Filing)AU$3.31M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding700,307,500
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.12Price Target Upside50.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$24.70M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA debt-to-equity of 0.10 indicates low leverage, which materially reduces insolvency risk and preserves financial flexibility. Over 2-6 months this supports continued R&D, partnership deals or working-capital support without immediate refinancing pressure, aiding strategic execution.
Diversified Revenue ModelMultiple revenue streams—clinical/consumer tests, contract research services and biopharma partnerships—create structural resilience. This platform-driven model allows cross-selling, scale benefits and recurring service opportunities that can stabilize revenues as each channel matures.
Positive Free Cash Flow GrowthFCF growth of 4.68% and free cash flow exceeding net income signal improving cash generation discipline. Over the medium term, this helps fund operations or selective investments, reducing reliance on external financing if the company can convert that trend into sustained operating cash flow.
Bears Say
Declining Revenue TrendA 24% revenue decline is a durable headwind: shrinking top-line undermines scale economics and weakens negotiating leverage with partners. Unless test volumes or contract intake recover, fixed costs and platform investments will pressure margins and long-term viability.
Sustained Operating LossesPersistent negative profitability means the core business is not yet self-sustaining. Over months this erodes equity, increases dependence on external capital, and constrains the ability to fund commercialization or longer R&D projects without dilution or cost-cutting that could slow growth.
Negative Operating Cash FlowNegative operating cash flow shows the company’s core activities are not generating cash. This structural shortfall requires either improved operating performance or financing; without correction, it threatens runway and limits investments needed to scale testing and partnership revenues.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.04 and its highest was AU$0.10 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$28.01M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
Microba Life Sciences Limited’s upcoming earnings report date is Sep 01, 2026 which is in 52 days.
How were Microba Life Sciences Limited’s earnings last quarter?
Microba Life Sciences Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.018 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.008.
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 700,307,500 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Microba Life Sciences Limited reported an EPS of -AU$0.018 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 1.176%.
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.12 (50.00% Upside)
AU$0.12 (50.00% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.76%
12-Months-Change
Fundamentals
Return on Equity
-63.04%
Trailing 12-Months
Asset Growth
-14.63%
Trailing 12-Months
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.12
▲(50.00% Upside)
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Options Prices
Currently, No data available
---